Centaurus Financial Inc. Acquires 996 Shares of Danaher Co. (NYSE:DHR)

Centaurus Financial Inc. grew its holdings in shares of Danaher Co. (NYSE:DHR) by 12.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 8,932 shares of the conglomerate’s stock after purchasing an additional 996 shares during the period. Centaurus Financial Inc.’s holdings in Danaher were worth $2,483,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of DHR. nVerses Capital LLC acquired a new position in Danaher during the 2nd quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the second quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the third quarter worth approximately $40,000. Darwin Wealth Management LLC bought a new stake in Danaher in the third quarter valued at approximately $55,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Danaher during the 2nd quarter valued at approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.3 %

Shares of NYSE DHR opened at $235.84 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a 50-day moving average price of $258.15 and a 200-day moving average price of $260.03. The stock has a market capitalization of $170.34 billion, a P/E ratio of 45.01, a P/E/G ratio of 4.32 and a beta of 0.85. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter in the previous year, the business earned $2.02 EPS. The company’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent analyst reports. Robert W. Baird dropped their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Finally, Wells Fargo & Company started coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.